In the case of HER2 positive gastro-esophageal cancers, the role of trastuzumab and the recombinant trastuzumab deruxtecan, with the attached topoisomerase inhibitor, seem to have made a breakthrough in these types of cancer and their treatment approach. This evidence concerns the gene ERBB2 and cancer.